Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
about
Reinventing diagnostics for personalized therapy in oncologyMulti-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.Biasogram: visualization of confounding technical bias in gene expression dataA systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.Point success rate for patient therapeutic response prediction by continuous biomarker scores.Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerPredictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistanceImportance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsLack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems.A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.An empirical assessment of validation practices for molecular classifiersUse of gene expression and pathway signatures to characterize the complexity of human melanoma.Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancerPredicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive valueTreatment-induced cell cycle kinetics dictate tumor response to chemotherapyPathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator.Intra- and interspecies gene expression models for predicting drug response in canine osteosarcomaCancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer.Personalized therapy for urothelial cancer: review of the clinical evidence.MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancerClinical nomogram to predict bone-only metastasis in patients with early breast carcinomaDrug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Modeling precision treatment of breast cancerBreast cancer, neoadjuvant chemotherapy and residual disease.Genomic approach towards personalized anticancer drug therapy.An update on chemotherapy and tumor gene expression profiles in breast cancer.Molecular tests as prognostic factors in breast cancer.Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience.A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.Integrative correlation: Properties and relation to canonical correlations.Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy.Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy.Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
P2860
Q28391395-474DC67F-2E92-4A8D-B4B1-DC0167989E15Q28480595-F007EC53-4229-4C15-ADB1-AE85C9B598B2Q28486222-BC540518-3345-4ECA-982C-55A68E99CD7CQ30423830-4C878120-05BE-429F-8839-FA4BFA09BED0Q30456795-0E478799-2582-40AD-BF94-4773EB7B56CDQ33684080-7FD1B1FA-3073-4F80-8E6B-0E710ACE45CEQ33692905-A9352318-7ADB-46A2-B5A6-A37568CEC382Q33919243-12EF9742-EE2F-40E1-BFBA-F3840D2F94B9Q34088408-A8887E32-F55E-4AAB-A0FF-46DAAD41221EQ34266467-E7A71822-3BC1-4503-8FDC-C2C0057497E6Q34300562-5C6A69DA-24D5-4D2F-AFC5-28FF36F0B188Q34933977-6410FD54-470F-422E-A33E-11B0629F9007Q35071486-D656F593-0BE3-4993-96CE-75564E1ABCBEQ35137142-11044A95-40B1-4511-B5F7-AD178BA4C0D5Q35402899-3014156F-BA19-456D-974D-04EC07DA7277Q35503492-48B87C14-BC66-4819-8D42-C3209A94C73CQ35740145-0E93E292-0C22-4F51-A5C7-452AEA6321A2Q35803615-605AF475-FCEF-4DAF-BB24-9D9A15708756Q35927860-D6144696-518B-4D44-BFA2-9744EB1B5A7EQ36037500-17EB1A5B-CDD7-4322-9DC8-3E639C72AE86Q36061792-8916F52A-E849-4935-990F-CB93ACAD0E11Q36062762-1C232386-B77F-4082-B7AA-E1674B27EFF9Q36157026-63EC6225-B7E7-45F1-B588-3CBFC27DCB09Q36204215-F73C66C1-DDE3-4214-8B5C-AE59144D38EAQ36295018-DECB4E86-9B33-4FC0-AF27-45B185EE5795Q36406956-D3297C05-BB95-4623-854A-8F998CD2BF35Q37608340-84D2559D-EE3E-4508-ADE4-BFDA28B2AB60Q37771115-6CCD162C-65BC-45C8-9C05-1639A9E0D0AAQ37976828-2B1DC10B-781D-4E20-A72D-893FE5E30ADFQ38017302-DEAD4286-61F0-4F7F-B868-F83B4A3F468CQ38184381-9DC0C58B-6409-41E3-941C-2095EEC6BEB8Q38404777-C4717537-4BEB-4425-9177-8AA1534110E5Q39751877-CC28CB14-7A8A-4501-855F-63765B2DF4CCQ41243909-08D1DD98-4841-416B-8844-927302D5BA1DQ42450983-B4040339-F631-4E4F-9C44-433830502F81Q47096783-1F0C9A7A-B764-4D05-9711-2681413ED3ECQ52621007-C8DFB340-DA89-4424-B53A-32B9ACAB4535Q54481772-F8D10F93-E686-4100-8026-703080AB568D
P2860
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prospective comparison of clin ...... chemotherapy in breast cancer.
@ast
Prospective comparison of clin ...... chemotherapy in breast cancer.
@en
type
label
Prospective comparison of clin ...... chemotherapy in breast cancer.
@ast
Prospective comparison of clin ...... chemotherapy in breast cancer.
@en
prefLabel
Prospective comparison of clin ...... chemotherapy in breast cancer.
@ast
Prospective comparison of clin ...... chemotherapy in breast cancer.
@en
P2093
P2860
P1476
Prospective comparison of clin ...... chemotherapy in breast cancer.
@en
P2093
Charles Coutant
Dan Theodorescu
Keith Baggerly
Lajos Pusztai
W Fraser Symmans
Young-Chul Kim
P2860
P304
P356
10.1158/1078-0432.CCR-09-2247
P407
P577
2010-01-12T00:00:00Z